Home » Topics » BioWorld Science

BioWorld Science
RSS

PolyActiva commences its first phase I trial of glaucoma treatment

Aug. 31, 2018

FDA approves Merck & Co.'s Delstrigo and Pifeltro for the treatment of HIV-1

Aug. 31, 2018

First patient enrolled in phase IIb/III trial of Anavex 2-73 for early Alzheimer's disease

Aug. 31, 2018

European Commission approves Onpattro for hATTR with polyneuropathy

Aug. 31, 2018

Xenon Pharmaceuticals tests antiepileptic NaV1.6 inhibitors in vivo

Aug. 31, 2018

Seven genes linked to plaque rupture in STEMI

Aug. 31, 2018

Novel cardiac biomarkers identified for heart failure, myocardial infarction

Aug. 31, 2018

Bristol-Myers Squibb patents receptor-interacting serine/threonine-protein kinase 1 inhibitors

Aug. 31, 2018

Pfizer terminates two ongoing domagrozumab studies for DMD

Aug. 31, 2018

Thanks for the memories: In bacteria, protein aggregates can protect from stress

Aug. 31, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...